Literature DB >> 33456444

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease.

Md Habibur Rahman1, Rokeya Akter2, Tanima Bhattacharya3, Mohamed M Abdel-Daim4,5, Saad Alkahtani4, Mohammed W Arafah4, Norah S Al-Johani4, Norah M Alhoshani4, Nora Alkeraishan4, Alhanof Alhenaky4, Omar H Abd-Elkader6, Hesham R El-Seedi7,8, Deepak Kaushik9, Vineet Mittal9.   

Abstract

Alzheimer's disease (AD) is a progressive cortex and hippocampal neurodegenerative disease which ultimately causes cognitively impaired decline in patients. The AD pathogen is a very complex process, including aggregation of Aβ (β-amyloid peptides), phosphorylation of tau-proteins, and chronic inflammation. Exactly, resveratrol, a polyphenol present in red wine, and many plants are indicated to show the neuroprotective effect on mechanisms mostly above. Resveratrol plays an important role in promotion of non-amyloidogenic cleavage of the amyloid precursor protein. It also enhances the clearance of amyloid beta-peptides and reduces the damage of neurons. Most experimental research on AD and resveratrol has been performed in many species, both in vitro and in vivo, during the last few years. Nevertheless, resveratrol's effects are restricted by its bioavailability in the reservoir. Therefore, scientists have tried to improve its efficiency by using different methods. This review focuses on recent work done on the cell and animal cultures and also focuses on the neuroprotective molecular mechanisms of resveratrol. It also discusses about the therapeutic potential onto the treatment of AD.
Copyright © 2020 Rahman, Akter, Bhattacharya, Abdel‐Daim, Alkahtani, Arafah, Al‐Johani, Alhoshani, Alkeraishan, Alhenaky, Abd‐Elkader, El‐Seedi, Kaushik and Mittal.

Entities:  

Keywords:  Alzheimer's disease; bioavailability; neuroprotective; oxidative stress; resveratrol; therapeutic agent

Year:  2020        PMID: 33456444      PMCID: PMC7804889          DOI: 10.3389/fphar.2020.619024

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  99 in total

Review 1.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

Review 2.  Therapeutic potential of resveratrol: the in vivo evidence.

Authors:  Joseph A Baur; David A Sinclair
Journal:  Nat Rev Drug Discov       Date:  2006-05-26       Impact factor: 84.694

3.  Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis.

Authors:  Jing Wang; Yun Zhang; Lu Tang; Nan Zhang; Dongsheng Fan
Journal:  Neurosci Lett       Date:  2011-08-27       Impact factor: 3.046

4.  The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol.

Authors:  K Teskac; J Kristl
Journal:  Int J Pharm       Date:  2009-10-13       Impact factor: 5.875

5.  Resveratrol is not a direct activator of SIRT1 enzyme activity.

Authors:  Dirk Beher; John Wu; Suzanne Cumine; Ki Won Kim; Shu-Chen Lu; Larissa Atangan; Minghan Wang
Journal:  Chem Biol Drug Des       Date:  2009-10-20       Impact factor: 2.817

Review 6.  The micronucleus assay in human buccal cells as a tool for biomonitoring DNA damage: the HUMN project perspective on current status and knowledge gaps.

Authors:  Nina Holland; Claudia Bolognesi; Micheline Kirsch-Volders; Stefano Bonassi; Errol Zeiger; Siegfried Knasmueller; Michael Fenech
Journal:  Mutat Res       Date:  2008-04-11       Impact factor: 2.433

7.  Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats.

Authors:  Roberta Schmatz; Cinthia Melazzo Mazzanti; Roselia Spanevello; Naiara Stefanello; Jessié Gutierres; Maisa Corrêa; Michelle Melgarejo da Rosa; Maribel A Rubin; Maria Rosa Chitolina Schetinger; Vera Maria Morsch
Journal:  Eur J Pharmacol       Date:  2009-03-19       Impact factor: 4.432

Review 8.  Neuropathology of Alzheimer's disease.

Authors:  Daniel P Perl
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

9.  Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity.

Authors:  Alberto Granzotto; Paolo Zatta
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

10.  Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia.

Authors:  Eduardo Candelario-Jalil; Antonio C Pinheiro de Oliveira; Sybille Gräf; Harsharan S Bhatia; Michael Hüll; Eduardo Muñoz; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2007-10-10       Impact factor: 8.322

View more
  28 in total

Review 1.  Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside.

Authors:  Fahadul Islam; Mohamed H Nafady; Md Rezaul Islam; Susmita Saha; Salma Rashid; Aklima Akter; Md Harun- Or-Rashid; Muhammad Furqan Akhtar; Asma Perveen; Ghulam Md Ashraf; Md Habibur Rahman; Sherouk Hussein Sweilam
Journal:  Mol Neurobiol       Date:  2022-05-12       Impact factor: 5.590

2.  Palliative Effect of Resveratrol against Nanosized Iron Oxide-Induced Oxidative Stress and Steroidogenesis-Related Genes Dysregulation in Testicular Tissue of Adult Male Rats.

Authors:  Mona M Ahmed; Mohamed M A Hussein; Taisir Saber; Yasmina M Abd-Elhakim
Journal:  Int J Environ Res Public Health       Date:  2022-07-04       Impact factor: 4.614

Review 3.  History in Perspective: The prime pathological players and role of phytochemicals in Alzheimer's disease.

Authors:  Mohd Sajad; Rajesh Kumar; Sonu Chand Thakur
Journal:  IBRO Neurosci Rep       Date:  2022-04-28

4.  Effects of Resveratrol Supplementation on the Cognitive Function of Patients with Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials.

Authors:  Jéssica Abdo Gonçalves Tosatti; Adriana Fialho da Silva Fontes; Paulo Caramelli; Karina Braga Gomes
Journal:  Drugs Aging       Date:  2022-02-21       Impact factor: 4.271

Review 5.  Resveratrol, Metabolic Dysregulation, and Alzheimer's Disease: Considerations for Neurogenerative Disease.

Authors:  Alex J T Yang; Ahmed Bagit; Rebecca E K MacPherson
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 6.  Evidence of Polyphenols Efficacy against Dry Eye Disease.

Authors:  Gaia Favero; Enrico Moretti; Kristína Krajčíková; Vladimíra Tomečková; Rita Rezzani
Journal:  Antioxidants (Basel)       Date:  2021-01-28

Review 7.  Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy.

Authors:  Ashwani Arya; Rubal Chahal; Rekha Rao; Md Habibur Rahman; Deepak Kaushik; Muhammad Furqan Akhtar; Ammara Saleem; Shaden M A Khalifa; Hesham R El-Seedi; Mohamed Kamel; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Vineet Mittal
Journal:  Biomolecules       Date:  2021-02-25

Review 8.  Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols.

Authors:  Meng Zhang; Guanhua Hu; Nan Shao; Yunpeng Qin; Qian Chen; Yan Wang; Peng Zhou; Biao Cai
Journal:  Inflammopharmacology       Date:  2021-08-04       Impact factor: 4.473

Review 9.  Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.

Authors:  Barbara Miziak; Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

Review 10.  Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease.

Authors:  Jesús Burillo; Patricia Marqués; Beatriz Jiménez; Carlos González-Blanco; Manuel Benito; Carlos Guillén
Journal:  Cells       Date:  2021-05-18       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.